Ralliant (NYSE:RAL) Downgraded by Wall Street Zen to "Buy"

Key Points

• Wall Street Zen downgraded Ralliant from “strong buy” to “buy,” though the broader analyst consensus remains “Moderate Buy,” with a $75.70 average price target.
• Ralliant shares rose 2.9% to $69.40, while the company’s latest quarterly earnings of $0.68 per share beat estimates by $0.05 on revenue of $567.8 million.
• Institutional interest increased significantly, including new stakes by BlackRock valued at approximately $1.04 billion and Flossbach Von Storch valued at about $222.5 million.

Ralliant (NYSE:RAL - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Tuesday.

Several other analysts have also recently issued reports on the company. Zacks Research raised Ralliant from a "hold" rating to a "strong-buy" rating in a report on Tuesday, June 30th. Truist Financial restated a "buy" rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. Evercore began coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an "outperform" rating and a $80.00 price objective for the company. Vertical Research cut shares of Ralliant from a "buy" rating to a "hold" rating and set a $65.00 price objective for the company. in a research note on Wednesday, May 27th. Finally, Citigroup upped their target price on shares of Ralliant from $81.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $75.70.

Ralliant Trading Up 2.9%

Ralliant stock opened at $69.40 on Tuesday. The business has a 50-day simple moving average of $67.79 and a two-hundred day simple moving average of $54.94. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The company has a market cap of $7.68 billion, a P/E ratio of -6.40, a P/E/G ratio of 2.51 and a beta of 1.61. Ralliant has a 52-week low of $37.27 and a 52-week high of $75.41.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating analysts' consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts predict that Ralliant will post 2.87 EPS for the current year.

Institutional Investors Weigh In On Ralliant

A number of hedge funds and other institutional investors have recently bought and sold shares of RAL. Frazier Financial Advisors LLC acquired a new stake in Ralliant in the second quarter valued at approximately $40,000. Flossbach Von Storch SE purchased a new stake in shares of Ralliant during the 2nd quarter valued at $222,460,000. BlackRock Inc. purchased a new stake in shares of Ralliant during the 2nd quarter valued at $1,039,481,000. Dunhill Financial LLC acquired a new stake in shares of Ralliant in the 2nd quarter worth $25,000. Finally, Deutsche Bank AG acquired a new stake in shares of Ralliant in the 2nd quarter worth $674,000.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source